Fig. 2.
Fig. 2. Analysis of the expansion kinetics of B6dom1-specific T cells and EL4 cells after intravenous injection of EL4 cells into naive and immunized mice. / B10 and B10.H7b mice were injected intravenously with 5 × 105 EL4 cells or B10 splenocytes on day 0 (+EL4 and +B10, respectively). B10.H7b recipients were either naive or preimmunized with 2 × 107 B10 splenocytes (αB10) intraperitoneally on day −14. (A) Number of EL4 cells (Thy1.2+CD4−CD8−Vβ12+) present in the spleen, inguinal lymph nodes, and BM (2 tibiae and femurs). Naive versus preimmunized mice: P = .04 for spleen and lymph node, and P = .007 for bone marrow on day 25. (B) Number of B6dom1-specific T cells (CD8+tet+) in the spleen and inguinal lymph nodes. Primed mice challenged with EL4 versus B10 cells:P = .004 on day 15. Results are depicted as the mean ± SD of 3 mice per group.

Analysis of the expansion kinetics of B6dom1-specific T cells and EL4 cells after intravenous injection of EL4 cells into naive and immunized mice.

B10 and B10.H7b mice were injected intravenously with 5 × 105 EL4 cells or B10 splenocytes on day 0 (+EL4 and +B10, respectively). B10.H7b recipients were either naive or preimmunized with 2 × 107 B10 splenocytes (αB10) intraperitoneally on day −14. (A) Number of EL4 cells (Thy1.2+CD4−CD8−Vβ12+) present in the spleen, inguinal lymph nodes, and BM (2 tibiae and femurs). Naive versus preimmunized mice: P = .04 for spleen and lymph node, and P = .007 for bone marrow on day 25. (B) Number of B6dom1-specific T cells (CD8+tet+) in the spleen and inguinal lymph nodes. Primed mice challenged with EL4 versus B10 cells:P = .004 on day 15. Results are depicted as the mean ± SD of 3 mice per group.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal